The primary endpoint of Overall Survival (OS) in the Combined FOXFIRE Analysis showed no statistically significant difference between...
Expert panel reaches uniform consensus that yttrium-90 microspheres is an appropriate option for patients with colorectal liver metastases...
Company Reports Significant Increase in Both Referring Physicians and Hospitals Certified to Administer Procedure Sirtex Medical Inc., a...
Americas Region Generates More Than 79 Percent of Global Revenue Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), has...
Increase of 18 Percent in Hospitals Certified to Administer Procedure Headline of release should read: Sirtex Medical Inc. Announces 21.2...
Increase of 18 Percent in Hospitals Certified to Administer Procedure Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited...
http://www.fool.com.au/2015/03/16/is-sirtex-medical-limited-set-to-make-a-blockbuster-announcement/
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), has announced that dose sales of SIR-Spheres® Y-90 resin...
First SIR-Spheres® microspheres treatment at Hospital Sirio-Libanes in Sao Paulo, Brazil Sirtex Medical Inc., a subsidiary of Sirtex...
Forty Consecutive Quarters of Dose Sales Growth Globally Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading...
Globally Sirtex Achieves 39 Consecutive Quarters of Dose Sales Growth Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited...
Sirtex and Guerbet Announce Collaboration On Clinical Studies in Liver Cancer PR Newswire SYDNEY, Australia and VILLEPINTE, France, March 24...
Sirtex and Guerbet to Collaborate on Clinical Studies in Primary and Secondary Liver Cancer PR Newswire SYDNEY and VILLEPINTE, France, March 24...
Sirtex and Guerbet Announce Collaboration On Clinical Studies in Liver Cancer PR Newswire PRINCETON, N.J., March 24, 2014 PRINCETON, N.J., March...
Globally Sirtex Achieves 38 Consecutive Quarters of Dose Sales Growth Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads